What this means
This study is still recruiting people, so no results are available yet. It aims to measure a brain signal system in healthy older adults and people with Parkinson's disease.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 20–80
- Where
- 1 site
The science
- Registered title
- In Vivo Noradrenergic System and Aging
- Trial ID
- NCT07569120 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Healthy Aging and Parkinson's Disease
- What is tested
- PET/MRI scanning session, Neuropsychological examination, Olfactory screening
- Sponsor
- Hospices Civils de Lyon
- Ages
- 20 Years to 80 Years
- Dates
- First posted May 6, 2026 · updated Jul 9, 2026
Registry summary
The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (here Parkinson's disease) through the use of a newly developed radiotracer visualizing alpha2C-ARs ([11C]ORM-13070) combined with a cutting-edge technology, the hybrid PET/MRI scanner. The secondary aim will be to determine whether the expected age- and PD-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (i.e. cognitive, motor and/or olfactory abilities).
Sites (1)
- Hôpital Neurologique Pierre Wertheimer - Service de Neurologie, Bron, France